The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease ; volume:12 ; number:5 ; day:15 ; month:4 ; year:2021 ; pages:1523-1534 ; date:5.2021
Diabetes therapy ; 12, Heft 5 (15.4.2021), 1523-1534, 5.2021
- Creator
-
Ehlers, Lars Holger
Lamotte, Mark
Monteiro, Sofia
Sandgaard, Susanne
Holmgaard, Pia
Frary, Evan C.
Ejskjaer, Niels
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-021-01040-y
- URN
-
urn:nbn:de:101:1-2021090819132589097658
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ehlers, Lars Holger
- Lamotte, Mark
- Monteiro, Sofia
- Sandgaard, Susanne
- Holmgaard, Pia
- Frary, Evan C.
- Ejskjaer, Niels
- SpringerLink (Online service)
Other Objects (12)
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME® trial
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients
Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure